LU90069I2 - Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip) - Google Patents

Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)

Info

Publication number
LU90069I2
LU90069I2 LU90069C LU90069C LU90069I2 LU 90069 I2 LU90069 I2 LU 90069I2 LU 90069 C LU90069 C LU 90069C LU 90069 C LU90069 C LU 90069C LU 90069 I2 LU90069 I2 LU 90069I2
Authority
LU
Luxembourg
Prior art keywords
zanidip
lercanidipine
derivatives
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
LU90069C
Other languages
English (en)
Original Assignee
Recordati Chem Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10556581&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90069(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati Chem Pharm filed Critical Recordati Chem Pharm
Publication of LU90069I2 publication Critical patent/LU90069I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
LU90069C 1984-02-14 1997-05-28 Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip) LU90069I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848403866A GB8403866D0 (en) 1984-02-14 1984-02-14 Diphenylalkylaminoalkyl esters

Publications (1)

Publication Number Publication Date
LU90069I2 true LU90069I2 (fr) 1997-07-23

Family

ID=10556581

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90069C LU90069I2 (fr) 1984-02-14 1997-05-28 Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)

Country Status (29)

Country Link
US (3) US4705797A (fr)
EP (1) EP0153016B1 (fr)
JP (1) JPS60199874A (fr)
KR (1) KR910005231B1 (fr)
AR (1) AR240804A1 (fr)
AT (1) ATE52772T1 (fr)
AU (1) AU570534B2 (fr)
BR (1) BR1101167A (fr)
CA (1) CA1277666C (fr)
DE (2) DE3577703D1 (fr)
DK (1) DK160985C (fr)
DZ (1) DZ748A1 (fr)
EG (1) EG17772A (fr)
ES (1) ES8602664A1 (fr)
FI (1) FI83954C (fr)
GB (1) GB8403866D0 (fr)
GR (1) GR850363B (fr)
HU (1) HU194171B (fr)
IE (1) IE57715B1 (fr)
IL (1) IL74238A (fr)
LU (1) LU90069I2 (fr)
MX (1) MX156874A (fr)
NL (1) NL970025I2 (fr)
NO (2) NO166123C (fr)
NZ (1) NZ210866A (fr)
PH (1) PH20725A (fr)
PT (1) PT79963B (fr)
SG (1) SG48590G (fr)
ZA (1) ZA85656B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561213B2 (en) * 1983-06-02 1987-04-30 Teijin Limited 1, 4-dihydropyridine derivative
US4994476A (en) * 1984-10-31 1991-02-19 Bristol-Myers Company Dihydropyridin-3,5-dicarboxylates incorporating aryloxypropanolamine moieties
DE3677319D1 (de) * 1985-10-22 1991-03-07 Sanwa Kagaku Kenkyusho Co Pharmazeutische 1,4-dihydropyridinderivate, ihre salze und herstellung.
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
JPH02149563A (ja) * 1988-11-30 1990-06-08 Nisshin Flour Milling Co Ltd ２−ハロエトキシカルボニル基を含有する１，４−ジヒドロピリジン誘導体の製造法
IT1274480B (it) * 1995-05-12 1997-07-17 Recordati Chem Pharm Procedimento migliorato per la preparazione della lercanidipina cloridrato
US5912351A (en) * 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
IT1279529B1 (it) * 1995-05-12 1997-12-16 Recordati Chem Pharm Procedimento di preparazione ed uso degli enantiomeri (s) di derivati 1,4-diidropiridinici per il trattamento dell'insufficienza cardiaca
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5851636A (en) * 1995-12-29 1998-12-22 Lantec Products, Inc. Ceramic packing with channels for thermal and catalytic beds
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
ITMI20011726A1 (it) * 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
ITMI20011727A1 (it) * 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi
ES2362998T3 (es) 2002-08-19 2011-07-18 Pfizer Inc. Terapia de combinación para enfermedades hiperproliferativas.
US20050101640A1 (en) * 2002-10-16 2005-05-12 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
US20040147566A1 (en) * 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
JP4901474B2 (ja) 2003-05-30 2012-03-21 ランバクシー ラボラトリーズ リミテッド 置換ピロール誘導体
WO2005107374A2 (fr) * 2004-05-07 2005-11-17 Sun Pharmaceutical Industries Limited Procede pour la preparation d'un derive d'acide 1,4-dihydropyridine-3,5-dicarboxylique
BRPI0513866A (pt) * 2004-07-26 2008-05-20 Cotherix Inc composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
US20060134212A1 (en) * 2004-09-02 2006-06-22 Forest Laboratories, Inc. Lercanidipine immediate release compositions
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
US20060165788A1 (en) * 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
KR100616276B1 (ko) * 2004-09-21 2006-08-28 일동제약주식회사 2,엔-디메틸-엔-(3,3-디페닐프로필)-1-아미노-2-프로판올의제조방법
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
KR100651212B1 (ko) * 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
IL165525A0 (en) * 2004-12-02 2006-01-15 Motivan Ltd Intermediates and a process for the manufacturing for antihypertensive dihydropyridine derivative suitable for pharmaceutical compositions
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
KR100638171B1 (ko) * 2005-03-25 2006-10-26 건일제약 주식회사 2,ｎ-디메틸-ｎ-(3,3-디페닐프로필)-1-아미노-2-프로판올의제조방법
EP1891009B1 (fr) 2005-06-15 2009-10-14 Hetero Drugs Limited Nouveau procede de preparation de la lercanidipine
BRPI0616169B8 (pt) 2005-09-16 2021-05-25 Glenmark Pharmaceuticals Ltd cloridrato de lercanidipina na forma polimorfa v, composição farmacêutica compreendendo dito composto e processos para preparação de cloridrato de lercanidipina
EP1963254A2 (fr) * 2005-09-21 2008-09-03 Torrent Pharmaceuticals Ltd Procede de preparation de la lercanidipine et forme amorphe d'hydrochlorure de lercanidipine
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP1951253A2 (fr) 2005-10-26 2008-08-06 Cotherix, Inc. Fasudil en polytherapies pour traiter l'hypertension arterielle pulmonaire
EP2351569B1 (fr) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil dans des thérapies combinées pour le traitement de l'hypertension artérielle pulmonaire
AU2006313430B2 (en) 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2007120135A1 (fr) * 2006-04-17 2007-10-25 Forest Laboratories, Inc. Composition à libération immédiate de lercanidipine
DE602006003877D1 (de) * 2006-05-24 2009-01-08 Cf Pharma Ltd Verfahren zur Herstellung von Lercanipidin
AU2007280407B2 (en) * 2006-08-04 2012-09-27 Recordati Ireland Limited Process for preparing amorphous lercanidipine hydrochloride
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
WO2008082041A1 (fr) * 2006-12-29 2008-07-10 Dongwoo Syntech Co., Ltd Procédé de préparation de chlorhydrate de lercanidipine
KR100848935B1 (ko) 2007-05-16 2008-07-29 주식회사 대희화학 생체 촉매 효소를 이용한 광학 선택적 가수분해방법
EP2585051B2 (fr) 2010-06-23 2020-04-08 KRKA, tovarna zdravil, d.d., Novo mesto Formes pharmaceutiques à usage oral comprenant de la lercanidipine et de l'énalapril et leurs sels pharmaceutiquement acceptables
WO2012037665A1 (fr) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Oxyde nitrique libérant un ester d'acide aminé pour le traitement de l'hypertension pulmonaire et autres états respiratoires
EP2444394A1 (fr) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Procédé de préparation de forme amorphe de lercanidipine HCI
EP2654729B1 (fr) 2010-12-24 2016-05-04 KRKA, d.d., Novo mesto Formes pharmaceutiques orales homogènes comprenant de la lercanidipine et de l'énalapril ou leurs sels pharmaceutiquement acceptables ainsi qu'un acide organique
WO2012123966A1 (fr) 2011-03-04 2012-09-20 Arch Pharmalabs Limited Procédé pour la préparation de 1,4-dihydropyridines substituées en position 4
EP2986599A1 (fr) 2013-04-17 2016-02-24 Pfizer Inc. Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
CA3125765A1 (fr) 2019-01-18 2020-07-23 Astrazeneca Ab Inhibiteurs de pcsk9 et leurs procedes d'utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985758A (en) * 1973-02-20 1976-10-12 Yamanouchi Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives
JPS5762257A (en) * 1980-10-03 1982-04-15 Yoshitomi Pharmaceut Ind Ltd 1,4-dihydropyridine-3,5-dicarboxylic acid ester or its salt
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
EP0080220B1 (fr) * 1981-11-17 1986-02-19 FISONS plc Dihydropyridines, leur procédé de préparation, leurs compositions et leur application comme médicaments
ATE50987T1 (de) * 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
AU561213B2 (en) * 1983-06-02 1987-04-30 Teijin Limited 1, 4-dihydropyridine derivative
NO854021L (no) * 1984-10-26 1986-04-28 Bayer Ag 1,4-dihydropyridin-hydroksyaminer og fremgangsmaate til fremstilling derav.
GB8503424D0 (en) * 1985-02-11 1985-03-13 Ici Plc Heterocyclic derivatives

Also Published As

Publication number Publication date
IL74238A (en) 1988-07-31
FI850535A0 (fi) 1985-02-08
MX156874A (es) 1988-10-08
DZ748A1 (fr) 2004-09-13
AR240804A1 (es) 1991-02-28
FI83954C (fi) 1991-09-25
DK63085A (da) 1985-08-15
NO850521L (no) 1985-08-15
PT79963B (en) 1986-11-10
EP0153016B1 (fr) 1990-05-16
SG48590G (en) 1990-08-17
PT79963A (en) 1985-03-01
IE57715B1 (en) 1993-03-10
GB8403866D0 (en) 1984-03-21
DK63085D0 (da) 1985-02-12
DE3577703D1 (de) 1990-06-21
ES540385A0 (es) 1985-11-16
BR1101167A (pt) 2004-08-17
EG17772A (en) 1991-08-30
HU194171B (en) 1988-01-28
NO2000011I1 (no) 2000-10-17
KR850005826A (ko) 1985-09-26
KR910005231B1 (ko) 1991-07-24
NO166123C (no) 1991-06-05
ZA85656B (en) 1985-08-28
FI850535L (fi) 1985-08-15
IE850280L (en) 1985-08-14
US4968832A (en) 1990-11-06
CA1277666C (fr) 1990-12-11
DE10199007I1 (de) 2001-04-12
JPH0517908B2 (fr) 1993-03-10
GR850363B (fr) 1986-02-06
FI83954B (fi) 1991-06-14
JPS60199874A (ja) 1985-10-09
NL970025I2 (nl) 1998-01-05
ATE52772T1 (de) 1990-06-15
AR240804A2 (es) 1991-02-28
NL970025I1 (nl) 1997-09-01
NO166123B (no) 1991-02-25
ES8602664A1 (es) 1985-11-16
DK160985B (da) 1991-05-13
DK160985C (da) 1991-11-04
EP0153016A3 (en) 1985-10-02
EP0153016A2 (fr) 1985-08-28
AU3868985A (en) 1985-09-12
NZ210866A (en) 1988-07-28
US4705797A (en) 1987-11-10
HUT37399A (en) 1985-12-28
IL74238A0 (en) 1985-05-31
US4772621A (en) 1988-09-20
DE10199007I2 (de) 2003-01-09
PH20725A (en) 1987-03-30
AU570534B2 (en) 1988-03-17

Similar Documents

Publication Publication Date Title
LU90069I2 (fr) Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)
LU91039I2 (fr) Proteq flu et ses dérivés pharmaceutiquement acceptables
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
LU90484I2 (fr) Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables
LU90219I2 (fr) Tolcapone et ses dérivés pharmaceutiquement acceptables (TASMAR)
LU88736I2 (fr) Cefquinome et ses dérivés pharmaceutiquement acceptables (COBACTAN)
LU90769I2 (fr) Capecitabine et ses d-riv-es pharmaceutiquement acceptables (xeloda)
LU90138I2 (fr) Etoposide phosphate et ses sels et dérivés pharmaceutiquement acceptables (etopophos)
LU88750I2 (fr) VENLAFAXINE et ses dérivés pharmaceutiquement acceptables
LU88576I2 (fr) RISPERIDONE et ses sels pharmaceutiquement acceptables (Risperdal R)
LU91147I2 (fr) Pemetrexed et ses sels pharmaceutiquement acceptables.
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
LU91452I2 (fr) "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"
LU90211I2 (fr) Miglitol et ses sels et dérivés pharmaceutiquement acceptables (diastabol)
NO941211D0 (no) Farmakologisk aktive pyrimidinforbindelser og fremgangsmåte for deres fremstilling
LU91072I2 (fr) Eplerenone et ses sels pharmaceutiquement acceptables - INSPRA
NO2001009I1 (no) Kvetiapin og farmasøytisk akseptable salter derav
KR910700249A (ko) 신규 치료학적 활성 화합물 및 그의 제조 방법
LU88334I2 (fr) 9-(1,3-Dihydroxy-2-propoxyméthyl) guanine et ses sels pharmaceutiquement acceptables.
LU91197I2 (fr) Azoxystrobin et folpel et leurs dérivés pharmaceutiquement acceptables (QUADRIS MAX).
LU90345I2 (fr) Ramipril + Felodipine et les sels physiologuiquement acceptables de ceux-ci (TAZKO)
MC2263A1 (fr) Aminobenzodiazepines et leurs sels pharmaceutiquement acceptables
DK264785D0 (da) Galenisk retardpraeparat
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
LU88843I2 (fr) Ropivacaine et ses dérivés pharmaceutiquement acceptables (Naropine R)